Branded generics and US generics manufacturer expanding into AI-driven marketing and compliance tools
Ajanta is a 50+ year-old pharma manufacturer with scale across India, emerging markets, and US generics. The tech stack reveals an aggressive move into AI: LLMs (OpenAI, Claude, Llama, Mistral), vector databases (Pinecone, Weaviate, FAISS), and agentic frameworks (LangChain, LangGraph) sit alongside design tools (Figma, Adobe suite) and enterprise systems (SAP, Salesforce, IQVIA). Active projects—LLM chatbots, voice systems, app launches—and stated pain points around scaling and operationalizing AI solutions suggest the company is automating customer engagement and internal workflows, not just selling pills.
Ajanta manufactures branded and generic pharmaceuticals from seven facilities across India, with US FDA-approved generics (50 ANDA approvals as of September 2025) and emerging-market presence in Africa, Southeast Asia, and Central Asia. Therapeutic focus in India spans cardiology, dermatology, ophthalmology, pain management, nephrology, and gynecology. The R&D operation employs over 850 scientists and targets 8–12 new ANDA filings annually. Manufacturing footprint includes formulation plants at Paithan and Dahej plus an API facility at Waluj. The company is a public entity with 10,000+ employees.
Design (Figma, Adobe XD, Photoshop, Illustrator), frontend (React, Angular, HTML, CSS), backend (.NET), enterprise (SAP, Salesforce, IQVIA), and AI/ML (OpenAI, Claude, Llama, Mistral, LangChain, LangGraph, FAISS, Pinecone, Weaviate, Hugging Face).
Mumbai, Maharashtra, India. Manufacturing operations span Paithan and Dahej in India, plus an API facility at Waluj.
50 commercialized ANDA approvals as of September 30, 2025, plus 2 tentative approvals and 22 ANDAs under FDA review.
Other companies in the same industry, closest in size